摘要:
A stable solid pharmaceutical composition consisting essentially of an effective amount of a salt of formula (II) together with an alkaline-reacting component maintaining the pH preferably above 8, or a salt with a divalent metal cation; and at least one pharmaceutical excipient; said salt of formula (II) being essentially stable during storage at room temperature for a period of at least 3 years. A process for stabilizing the salt of formula (II). A crystalline salt of formula (II) and a process for preparing said salt.
摘要:
The invention relates to a method for the treatment of tumors in mammals by the administration of compounds of the general formula (I) wherein A is O41 or NR42 R43 wherein R41 is hydrogen or a pharmaceutically acceptable inorganic or organic cation, or CORA wherein RA is alkyl and aryl; R42 and R43 are hydrogen, C1-C4-alkyl, cyclopropyl, cyclopentyl or cyclohexyl; or R42 is benzyl or phenethyl, optionally mono- or disubstituted by methyl, iso-propyl methoxy, fluoro, chloro, bromo, dimethylamino, trifluoromethyl or nitro and R43 is hydrogen; or R42 and R43 form a 5- or 6-membered ring; or R42 is CORB wherein RB is alkyl or aryl, —CH2N(CH3)2 or —CH2CH2COOH or CORB is a 2-acyloxymethylbenzoyl group wherein RC is methyl, ethyl, phenyl or benzyl; R42 is COORD wherein RD is C1-C4-alkyl, phenyl or benzyl; or R42 is —CH2OCO-tert.-butyl or R42 is CONRFRG wherein RF and RG are C1-C4-alkyl; or R42 is CXNHRE wherein X is O or S and RE is C1-C4-alkyl, C2-C4-alkyl functionalized with an tertiary amino group, or phenyl, optionally functionalised with a p-chloro group; or R42 is CH2NRHRI wherein RH and RI are C1-C4-alkyl and RH and RI form a morpholine ring and R43 is hydrogen, C1-C2-alkyl or cyclopropyl; R is hydrogen, C1-C4-alkyl or allyl; with the proviso that R is not hydrogen when A is OR41; R′ is hydrogen, methyl, methoxy, fluoro, chloro, bromo, cyano, nitro, azido, trifluoromethyl, or OCHxFy, wherein x=0-2, y=1-3 with the proviso that x+y=3; and that R′ is not hydrogen when R is methyl and A is OR41; R″ is hydrogen, fluoro or chloro, with the proviso that R″ is fluoro or chloro only when R′ is fluoro or chloro; R5 is hydrogen, C1-C3-alkyl; methoxy, ethoxy, thio-C1-C3-alkyl fluoro, chloro, bromo, trifluoromethyl, nitro, amino, dimethylamino or OCHxFy, or OCH2CHxFy wherein x=0-2, y=1-3 with the proviso that x+y=3 and that R5 is not fluoro or amino when A is OR41; and that R5 is hydrogen only when A is NR42 R43 and R′ is trifluoromethyl; R6 is hydrogen; or R5 and R6 taken together are methylenedioxy, or any tautomer, optical isomer or racemate thereof. The invention also comprises novel compounds, therapeutic compositions and processes for the preparation of the compounds of formula I.
摘要:
A stable solid pharmaceutical composition consisting essentially of an effective amount of a crystalline salt of formula (II) together with an alkaline-reacting component maintaining the pH preferably above 8, or a salt with a divalent metal cation; and at least one pharmaceutical excipient; said salt of formula (II) being essentially stable during storage at room temperature for a period of at least 3 years. A process for stabilizing the salt of formula (II). A crystalline salt of formula (II) and a process for preparing said salt.
摘要:
A compound of formula (I) wherein R is methyl, ethyl, n-propyl, iso-propyl, n-butyl or allyl; R′ is hydrogen, C1-C4 alkyl, C1-C3 alkoxy; halogen, trifluoromethyl or OCHxFy, R″ is hydrogen, fluoro or chloro, that R″ being fluoro or chloro only when R′ is fluoro or chloro; R3 is hydrogen or C1-C5 alkyl R4 is hydrogen, CH2OCOC(CH3)3, pharmaceutically acceptable inorganic or organic cations, or COR4′ wherein R4′ is C1-C5 alkyl, phenyl, benzyl or phenethyl; R7 is methyl or ethyl; one of A and B is sulphur and the other is C-R2; when A is S, R2 is selected from hydrogen and methyl, with the proviso that R2 is methyl only when R3 is not hydrogen; and when B is S, R2 is hydrogen; and any tautomer thereof. A pharmaceutical composition comprising a compound of formula (I), a method of treating malignant tumours or diseases resulting from autoimmunity or pathologic inflammation.
摘要翻译:式(I)的化合物,其中R是甲基,乙基,正丙基,异丙基,正丁基或烯丙基; R'是氢,C 1 -C 4烷基,C 1 -C 3烷氧基; 卤素,三氟甲基或OCH x F y,R“是氢,氟或氯,只有当R'是氟或氯时,R”是氟或氯; R3是氢或C1-C5烷基R4是氢,CH2OCOC(CH3)3,药学上可接受的无机或有机阳离子,或COR4',其中R4'是C1-C5烷基,苯基,苄基或苯乙基; R7是甲基或乙基; A和B之一是硫,另一个是C-R2; 当A为S时,R2选自氢和甲基,条件是仅当R3不为氢时R2为甲基; 当B为S时,R 2为氢; 及其互变异构体。 一种药物组合物,其包含式(I)化合物,治疗恶性肿瘤的方法或由自身免疫或病理性炎症引起的疾病。
摘要:
A stable solid pharmaceutical composition consisting essentially of an effective amount of a salt of formula (II) together with an alkaline-reacting component maintaining the pH preferably above 8, or a salt with a divalent metal cation; and at least one pharmaceutical excipient; said salt of formula (II) being essentially stable during storage at room temperature for a period of at least 3 years. A process for stabilizing the salt of formula (II). A crystalline salt of formula (II) and a process for preparing said salt.
摘要:
A system for controlling the cooling of small milk quantities in a cooling tank (4). An agitation pipe (2) extended through a regular milk outlet (26) in a first end wall (6) of the tank is provided, having a nozzle end (32) for introducing incoming/re-circulated milk onto a milk cooling surface (14) at a predetermined position (dp). The position (dp) being situated (1) between a first end wall (6) and a central part of the tank (4) and laterally displaced (b) relative to the perpendicular central axis of the tank. The nozzle end (32) is directed towards a second end wall (8) of the tank (4). Agitation is performed by the agitation pipe (2) upon demand or when the milk quantity is insufficient for a regular agitator element (27) to work properly.
摘要:
A method includes the steps of recording milk yields (MY?1#191, MY?2#191, MY?N#191) from milkings of an udder quarter or udder of a milking animal; recording the times (t1, t2, . . . , tN) of the milkings; calculating milk secretion rates (MSR1, MSR2, . . . , MSRN) for said udder quarter or udder based on the milk yields and times; fitting a time dependent function (F(t)) to the calculated secretion rates, said time dependent function comprising one portion, which increases with time, and one portion, which decreases with time; estimating an expected milk secretion rate (EMSRt1+N) for said udder quarter or udder at a time (tN+1) following the last milking based on said function (F(t)); determining an expected milk yield (EMYtN+1) for said udder quarter or udder at said time based on the expected secretion rate and, at said time, the time period lapsed since last milking; and initiating an action to be performed with respect to said animal depending on said expected milk yield.
摘要翻译:一种方法包括从哺乳动物的乳房四分之一或乳房的乳汁中记录乳产量(MY≥1#191,MY≥2#191,MY≤N#191)的步骤; 记录乳汁的时间(t 1> 1,t 2 2,...,t N N N); 基于牛奶产量计算所述乳房季度或乳房的乳汁分泌率(MSR <1>,MSR 2>,...,MSR N N) 和时代 将时间依赖函数(F(t))拟合到所计算的分泌速率,所述时间依赖函数包括随时间增加的一部分和随时间减少的一部分; 基于所述功能估计在最后一次挤奶之后的时间(t N N + 1),所述乳房四分之一或乳房的预期乳分泌率(EMSR ) F(t)); 基于预期的分泌速率确定所述乳房季度或乳房在所述乳房季度或乳房的预期乳产量(EMYTN + 1N),并且在所述时间,自上次挤奶后经过的时间段; 并根据所述预期的产奶量开始相对于所述动物进行的动作。
摘要:
The present invention relates to a tool as well as a blank for manufacturing of the tool. The tool is made of solid cemented carbide and includes a shank for mounting in a rotatable spindle and chip flutes. Lines of intersection between the chip flutes and clearance surfaces form cutting edges at a cutting end of the tool. The flush channels extend through the entire tool in order to transfer flushing medium to the cutting end of the tool. The flush channels have varying pitch.
摘要:
Compounds of formula (I) and tautomers thereof are effective for the treatment of mammals suffering from diseases resulting from autoimmunity and pathological inflammation.
摘要:
Use of a compound of formula (I) and the pharmaceutically acceptable acid addition salts thereof, wherein R1 is either halogen or hydrogen and R2 is halogen; X is CH2, O or S; R3 and R4 are the same or different and selected from hydrogen or lower alkyl; n is 2 or 3; A is selected from the pyrimidyl- or pyridyl-groups (a), (b) or (c) wherein R5, R6 and R7 are as defined in the description; for the manufacture of a medicament for the relief or prevention of a withdrawal syndrome resulting from addiction to a drug or substance of abuse or for treatment thereof.